

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** Unknown  
**Gender:** Unknown  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Cerebral Cavernous Malformation Panel, Sequencing and Deletion/Duplication**

ARUP test code 3002286

Cerebral Cavernous Malformation Specimen      whole Blood

Cerebral Cavernous Malformation Interp      Positive

**H=High, L=Low, \*=Abnormal, C=Critical**

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 20-329-112575  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 1 of 3 | Printed: 12/3/2020 9:53:36 AM  
4848

**BACKGROUND INFORMATION:** Cerebral Cavernous Malformation Panel, Sequencing and Deletion/Duplication

**CHARACTERISTICS:** Cerebral cavernous malformations (CCMs) are vascular malformations occurring in the brain or other CNS locations, which involve closely clustered, enlarged capillary channels without normal intervening brain parenchyma. CCMs do not always cause clinical symptoms, but may result in intracranial hemorrhage, seizures, headaches, or focal neurological deficits without intracranial bleed. Familial CCM (FCCM) is defined by the presence of multiple CCMs, a single CCM and at least one family member with one or more CCM, or a pathogenic heterozygous variant in one of the associated genes (KRIT1, CCM2, or PDCD10).

**EPIDEMIOLOGY:** CCMs occur in approximately 0.4-0.5 percent of the general population. FCCM is estimated to occur in 1:2,000 to 1:10,000 individuals. Up to 20 percent of all CCMs are familial.

**CAUSE:** Pathogenic germline variants in CCM2, KRIT1 (CCM1), or PDCD10 (CCM3).

**INHERITANCE:** Autosomal dominant with reduced penetrance.

**PENETRANCE:** Up to 50 percent of individuals with a molecular diagnosis of FCCM remain clinically asymptomatic.

**CLINICAL SENSITIVITY:** 85-95 percent for FCCM.

**GENES TESTED:** CCM2, KRIT1, PDCD10.

**METHODOLOGY:** Targeted capture of all coding exons and exon-intron junctions of the targeted genes, followed by massively parallel sequencing. Sanger sequencing was performed as necessary to fill in regions of low coverage and confirm reported variants. A custom tiled comparative genomic hybridization array (aCGH) was used to detect large deletions or duplications in the indicated subset of genes. Human genome build 19 (Hg 19) was used for data analysis.

**ANALYTICAL SENSITIVITY/SPECIFICITY:** The analytical sensitivity of this test is approximately 99 percent for single nucleotide variants (SNVs) and greater than 93 percent for insertions/duplications/deletions from 1-10 base pairs in size. Variants greater than 10 base pairs may be detected, but the analytical sensitivity may be reduced.

**LIMITATIONS:** A negative result does not exclude a diagnosis of FCCM. This test only detects variants within the coding regions and intron-exon boundaries of the targeted genes. Regulatory region variants and deep intronic variants will not be identified and breakpoints of large deletions/duplications will not be determined. Single exon deletions/duplications or deletions/duplications less than 1kb may not be detected. Deletions/duplications/insertions of any size may not be detected by massively parallel sequencing. Diagnostic errors can occur due to rare sequence variations. This assay may not detect low-level mosaic or somatic variants associated with disease. Interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplantation. Non-coding transcripts were not analyzed.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement C: aruplab.com/CS

**H=High, L=Low, \*=Abnormal, C=Critical**

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Cerebral Cavernous Malformation Specimen	20-329-112575	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Cerebral Cavernous Malformation Interp	20-329-112575	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

*Unless otherwise indicated, testing performed at:*

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 20-329-112575  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 3 of 3 | Printed: 12/3/2020 9:53:36 AM  
4848